14.40
+0.96
+(7.14%)
At close: 3:29:02 PM GMT+1
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 5.26M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| BERGMANN ANTHONY Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 2, 2025 |
| KRASNEY KAREN General Counsel | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 11,120 | Dec 13, 2024 |
| LITVACK FRANK I Director | Conversion of Exercise of derivative security at price 1.10 per share. | Indirect | 22,430 | Dec 3, 2024 |
| NIPPON SHINYAKU CO., LTD. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.36 per share. | Direct | 14,999,998 | Sep 20, 2024 |
| MUSKET DAVID B Director | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 47,260 | Aug 7, 2024 |
| MUSKET DAVID B Director | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 22,457 | Apr 23, 2024 |
| COLLIER EARL M JR Director | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 41,700 | Apr 23, 2024 |
| BERGMANN ANTHONY Chief Financial Officer | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 3,027 | Oct 23, 2023 |
| MUSKET DAVID B Director | Purchase at price 2.75 per share. | Direct | 1,128 | Oct 12, 2023 |
| COLLIER EARL M JR Director | Purchase at price 2.83 per share. | Direct | 28,300 | Oct 10, 2023 |
| MUSKET DAVID B Director | Purchase at price 2.82 per share. | Direct | 14,334 | Oct 9, 2023 |
| AUWAERTER PAUL GISBERT Director | Purchase at price 2.84 per share. | Direct | 14,200 | Oct 6, 2023 |
| MUSKET DAVID B Director | Purchase at price 2.90 per share. | Direct | 7,250 | Oct 4, 2023 |
| LITVACK FRANK I Director | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 28,840 | Aug 14, 2023 |
| MARBAN LINDA Chief Executive Officer | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 28,841 | May 12, 2023 |
| AVAT XAVIER Former | Sale at price 4.29 per share. | Direct | 63,372 | Apr 17, 2023 |
| AVAT XAVIER Former | Conversion of Exercise of derivative security at price 3.46 per share. | Direct | 293,377 | Apr 5, 2023 |
| AVAT XAVIER Former | Sale at price 4.06 per share. | Direct | 12,180 | Mar 28, 2023 |
| LITVACK FRANK I Director | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 19,498 | Feb 21, 2023 |
| MANZO LOUIS Director | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 1,947 | Feb 21, 2023 |
| COLLIER EARL M JR Director | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 1,947 | Feb 14, 2023 |
| DUNBAR GEORGE W JR Director | Conversion of Exercise of derivative security at price 1.39 per share. | Direct | 1,947 | Feb 14, 2023 |
Related Tickers
2LB.BE Iovance Biotherapeutics Inc
5.99
+0.67%
2LB.F Iovance Biotherapeutics, Inc.
5.99
+0.77%
MOOD.CN Doseology Sciences Inc.
0.1200
0.00%
IFRX InflaRx N.V.
2.4100
+1.69%
SLRX Salarius Pharmaceuticals, Inc.
2.2400
+4.19%
AUTL Autolus Therapeutics plc
2.2100
+0.45%
CABA Cabaletta Bio, Inc.
2.3900
+2.14%
CTXR Citius Pharmaceuticals, Inc.
2.6900
-4.95%
CRDF Cardiff Oncology, Inc.
4.0300
+1.51%
HOTH Hoth Therapeutics, Inc.
1.2600
-1.56%